Sutro Biopharma Announces Major Restructuring, Cuts Workforce by One-Third to Extend Cash Runway Through 2027

Reuters

2025/09/30

Sutro Biopharma Announces Major Restructuring, Cuts Workforce by One-Third to Extend Cash Runway Through 2027

**Sutro Biopharma Announces Corporate Restructuring to Extend Cash Runway** SOUTH SAN FRANCISCO, Calif., September 29, 2025 - Sutro Biopharma Inc. (NASDAQ: STRO), a biotechnology company specializing in antibody drug conjugates (ADCs) for cancer treatment, has announced a major organizational restructuring. The company will reduce its workforce by approximately one-third to focus resources on advancing its three key ADC programs and research collaborations. This move, combined with anticipated near-term milestone payments, is expected to extend the company's financial runway into at least mid-2027. Sutro plans to advance its next-generation Tissue Factor-targeting exatecan ADC, STRO-004, into clinical trials this year, with initial data expected in 2026. CEO Jane Chung said the changes will help the company reach critical development milestones and deliver value to patients and shareholders.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sutro Biopharma Inc. published the original content used to generate this news brief on September 29, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2571363561"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571363561\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571363561?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-30 05:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571363561","market":"nz","top_or_hot":-1,"title":"Sutro Biopharma Announces Major Restructuring, Cuts Workforce by One-Third to Extend Cash Runway Through 2027","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sutro Biopharma Announces Major Restructuring, Cuts Workforce by One-Third to Extend Cash Runway Through 2027\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **Sutro Biopharma Announces Corporate Restructuring to Extend Cash Runway** SOUTH SAN FRANCISCO, Calif., September 29, 2025 - <a href=\"https://laohu8.com/S/STRO\">Sutro Biopharma Inc</a>. (NASDAQ: STRO), a biotechnology company specializing in antibody drug conjugates (ADCs) for cancer treatment, has announced a major organizational restructuring. The company will reduce its workforce by approximately one-third to focus resources on advancing its three key ADC programs and research collaborations. This move, combined with anticipated near-term milestone payments, is expected to extend the company's financial runway into at least mid-2027. Sutro plans to advance its next-generation Tissue Factor-targeting exatecan ADC, STRO-004, into clinical trials this year, with initial data expected in 2026. CEO Jane Chung said the changes will help the company reach critical development milestones and deliver value to patients and shareholders.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sutro Biopharma Inc. published the original content used to generate this news brief on September 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sutro Biopharma Announces Major Restructuring, Cuts Workforce by One-Third to Extend Cash Runway Through 2027</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSutro Biopharma Announces Major Restructuring, Cuts Workforce by One-Third to Extend Cash Runway Through 2027\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-30 05:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sutro Biopharma Announces Major Restructuring, Cuts Workforce by One-Third to Extend Cash Runway Through 2027\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **Sutro Biopharma Announces Corporate Restructuring to Extend Cash Runway** SOUTH SAN FRANCISCO, Calif., September 29, 2025 - <a href=\"https://laohu8.com/S/STRO\">Sutro Biopharma Inc</a>. (NASDAQ: STRO), a biotechnology company specializing in antibody drug conjugates (ADCs) for cancer treatment, has announced a major organizational restructuring. The company will reduce its workforce by approximately one-third to focus resources on advancing its three key ADC programs and research collaborations. This move, combined with anticipated near-term milestone payments, is expected to extend the company's financial runway into at least mid-2027. Sutro plans to advance its next-generation Tissue Factor-targeting exatecan ADC, STRO-004, into clinical trials this year, with initial data expected in 2026. CEO Jane Chung said the changes will help the company reach critical development milestones and deliver value to patients and shareholders.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sutro Biopharma Inc. published the original content used to generate this news brief on September 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nNDL5Fy3Tn:1","article_id":"2571363561","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571363561","pubTimestamp":1759179770,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"**Sutro Biopharma Announces Corporate Restructuring to Extend Cash Runway** SOUTH SAN FRANCISCO, Calif., September 29, 2025 - Sutro Biopharma Inc. , a biotechnology company specializing in antibody drug conjugates  for cancer treatment, has announced a major organizational restructuring. The company will reduce its workforce by approximately one-third to focus resources on advancing its three key ADC programs and research collaborations. This move, combined with anticipated near-term milestone payments, is expected to extend the company's financial runway into at least mid-2027. Sutro plans to advance its next-generation Tissue Factor-targeting exatecan ADC, STRO-004, into clinical trials this year, with initial data expected in 2026. CEO Jane Chung said the changes will help the company reach critical development milestones and deliver value to patients and shareholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","STRO":"Sutro Biopharma Inc"},"translate_title":"Sutro Biopharma宣布重大重组，裁员三分之一，以将现金跑道延长至2027年","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"STRO":0.9},"content_text":"Sutro Biopharma Announces Major Restructuring, Cuts Workforce by One-Third to Extend Cash Runway Through 2027\n    \n\n        **Sutro Biopharma Announces Corporate Restructuring to Extend Cash Runway** SOUTH SAN FRANCISCO, Calif., September 29, 2025 - Sutro Biopharma Inc. (NASDAQ: STRO), a biotechnology company specializing in antibody drug conjugates (ADCs) for cancer treatment, has announced a major organizational restructuring. The company will reduce its workforce by approximately one-third to focus resources on advancing its three key ADC programs and research collaborations. This move, combined with anticipated near-term milestone payments, is expected to extend the company's financial runway into at least mid-2027. Sutro plans to advance its next-generation Tissue Factor-targeting exatecan ADC, STRO-004, into clinical trials this year, with initial data expected in 2026. CEO Jane Chung said the changes will help the company reach critical development milestones and deliver value to patients and shareholders.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sutro Biopharma Inc. published the original content used to generate this news brief on September 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}